{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT SAE's SPONSORED"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP004"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th 12 November 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 November 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "25/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th November 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: November 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Caroline Fox"
                    },
                    {
                        "text": "Research Nurse"
                    },
                    {
                        "text": "25/07/2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "SOP-01- SOP on SOPs SOP-04- SAEs (Hosted) SOP-05- TMF (Sponsored) SOP-06- Research Staff Training SOP-08- Amendments SOP-09- Serious Breaches (Sponsored) SOP-15- DSURs (Sponsored)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th November 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Applicable to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 10.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Equality impact assessment  10 Appendix 1: Definitions Appendix 2: SAE reporting flowchart"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 3: SUSAR report form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 4: Notification of amendment for urgent safety measures Appendix 5: Pregnancy notification form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 6: Preliminary equality analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the adverse event reporting procedures to be followed by all staff who are involved in setting up and running research studies managed or sponsored by Mid Essex Hospital Services NHS Trust."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on the responsibilities delegated to the Chief Investigator (CI) by the sponsor regarding adverse event reporting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "To outline responsibilities for assessment of seriousness, causality, severity and expectedness of safety events by the sponsor and investigator"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "To outline procedures for Adverse Event (AE)/Serious Adverse Event (SAE)/Serious Adverse Reaction (SAR) recording and reporting requirements for Trust sponsored clinical trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "To outline the Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting process to sponsor, MHRA, Ethics and participating sites (for multicentre trials)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.4,
                "text": "To outline Development Safety Update Report (DSUR) submission"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 2.5,
                "text": "To outline details of safety event trend analysis and monitoring by sponsor and/or investigator"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with clinical research including, but not limited to, Chief Investigators (CI), Principal Investigators (PI), Consultants, Co-Investigators, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators, Administrative Staff and Clinical Trial Administrators."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "For Trust sponsored drug trials, the responsibility for pharmacovigilance is delegated to the CI. The CI should ensure the pharmacovigilance responsibilities are delegated to appropriately trained and qualified individuals and is recorded in a delegation log as described in gSOP-06. Throughout this document, this delegated individual will be referred to as \u2018DI'."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "The CI shall also ensure that all study personnel involved in conducting sponsored trials attend SOP training sessions provided by the R&D Office and evidence of this maintained with the study personnel training files (see gSOP-07)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Recording and Reporting Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 All adverse events/adverse reactions should be recorded in the source data (medical records, unless the protocol states particular adverse events/adverse reactions are exempt from recording or reporting)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 Adverse events and adverse reactions should be reviewed by a clinician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "5.1.3 The severity of adverse events and adverse reactions should also be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "5.1.4 For multicentre trials, the CI or DI may not always agree on the grading of an event. Please ensure that the highest grading is used for reporting purposes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "5.1.5 Events considered serious, should follow procedures outlined in 5.2."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Recording and Reporting Serious Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "5.2.1 A Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) must be recorded and reported according to the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 Any research personnel who observes an SAE is responsible for notifying the CI or DI within 24 hours of knowledge, unless the protocol states this event is exempt from immediate reporting. If this is the case, the SAE should be recorded in the patient's CRF (Case Report Form) and the relevant SAE log."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "5.2.3 Seriousness must always be assessed by a medically qualified doctor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "5.2.4 The CI or DI should review whether the event is classed as serious, i.e. if the event results in one or more of the criteria listed above or has been identified within the protocol or reference document (e.g. Investigator's Brochure or Summary of Product Characteristics) as an SAE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "5.2.5 The CI or DI should record the classification of the seriousness as per protocol recording requirements (e.g. CRF/SAE form)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "5.2.6 Causality must always be assessed by a medically qualified doctor. The Sponsor may also make an independent assessment of causality."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "5.2.7 The CI or DI should assess the causality of the event, by considering whether the event has any relationship to the administered study medication, as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Events which are Definitely, Probably or Possibly related are Serious Adverse Reactions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Events which are Unlikely or Unrelated are Serious Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "5.2.8 This assessment should be recorded as per protocol requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "5.2.9 All adverse events judged by either the Investigator or Sponsor as having a reasonable suspected causal relationship to an IMP qualify as adverse reactions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "5.2.10 The Investigator's decision should be independent of the Sponsor. In the case where the Sponsor assessment differs from that of the Investigator's assessment, under no circumstances should the Sponsor downgrade the Investigator's assessment. If the Sponsor disagrees with the Investigator's causality assessment, both the opinion of the Investigator and the Sponsor should be provided on the report. This disagreement should also be fully documented."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "5.2.11 For serious adverse reactions, the CI or DI should carry out the expectedness assessment using the reference information (either the Summary of Product Characteristics (SmPC) or Investigator's Brochure (IB)) as stated in the protocol. If the nature, seriousness, severity or outcome of the reaction(s) is not consistent with the reference information for the Investigational Medicinal Product (IMP), they should be considered unexpected."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "5.2.12 The Sponsor's Representative will review the expectedness of all SARs against the Reference Safety Information (RSI)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "5.2.13 Expectedness decisions must be based purely on the content of the RSI in either the IB or SmPC; other factors such as the subject population and subject history should not be taken into account. Expectedness is not related to what is an anticipated event within a particular disease."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "5.2.14 Current versions of the SmPC should be printed and a hard-copy kept in the Trial Master File (TMF). Research teams should check periodically for updates to the SmPC. If the SmPC has not been updated since the last check, then the previous copy can be kept in the file, with a file note listing the dates of update checks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "5.2.15 IBs should either be kept in the TMF or in a central file with a file note stating the current version and its location."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "5.2.16 When IBs are updated with no change to the safety information, please send a copy to the R&D Department for notification."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "5.2.17 When IBs are updated with a change to the safety information, this should be treated as a substantial amendment (gSOP-09). An electronic copy of the IB should also be forwarded to the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "5.2.18 Where electronic copies are not available, a hard-copy of the front sheet should be forwarded to the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "5.2.19 The CI/DI should ensure that the seriousness, causality, expectedness and severity assessments are documented according to the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "5.2.20 All SAEs should be followed-up until resolution and this must be documented in the source information and/or study specific documents."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "text": "5.2.21 The SAE flow chart (appendix 2) can be used to assess SAEs and decide if the event requires further expedited reporting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "5.2.22 All SAEs should be followed up until resolution and subsequent follow-up reports submitted as per protocol requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "5.2.23 Events listed as expected and not requiring expedited reporting in the protocol do not need reporting but will need to be recorded according to the protocol and included in the annual line-listing (gSOP-16)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Recording and Reporting SUSARs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 Events identified as serious, related (or possibly/probably related) and unexpected, should be classed as Suspected Unexpected Serious Adverse Reactions (SUSARs)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 For Trust sponsored studies, the CI/DI is responsible for reporting SUSARs to the regulatory authorities and any participating sites according to the protocol and site agreements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.3.3 SUSARs must be reported to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "\u25cf MHRA : eSUSAR database The R&D Department has been provided with a login and administrator status and can delegate reporting responsibilities to the Research Team and provide them with a login to the eSUSAR database. SUSAR details need to be entered into this database and a copy filed in the Trial Master File."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "\u25cf HRA: Safety Reporting Form (CTIMPs)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "\u25cf R&D Office: SUSAR Reporting Form (Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "5.3.4 The timelines for SUSAR reporting purposes starts at day \u20180', which is the day that the Sponsor actually receives the information containing the minimum reporting criteria and not the day the Sponsor picks up and processes this information."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "5.3.5 Initial reports for fatal or life-threatening SUSARs must be reported to the MHRA and REC within 7 calendar days from knowledge. Any follow-up reports must be reported and submitted within a further 8 days. The R&D Office must also be notified as soon as the team are aware of the SUSAR."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "5.3.6 For all other SUSARs, the initial report should be submitted within 15 calendar days to the MHRA, Ethics and R&D Office. Follow-up reports should be submitted as soon as available or as per protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "text": "5.3.7 If there is any suspicion that a SAR is caused by a non-IMP interacting with an IMP, then this should be reported as a SUSAR."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "5.3.8 As a general rule treatment codes should be broken by the sponsor before reporting a SUSAR to the MHRA and Ethics committee. The unblinding of a single subject should only be carried out if it is important to the subject's safety. For further guidance, refer to the EC Guidance."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "5.3.9 If the CI/DI decides not to unblind a SUSAR during the expedited reporting process, appropriate documented justification for this decision should be made. A copy of the documentation should be filed within the TMF and a copy provided to R&D with the SUSAR report form."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "Unblinding in relation to SUSAR Reporting:"
            }
        },
        {
            "type": "image",
            "sequence_num": 79,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "5.3.10 Completed SUSAR report forms should be sent in the first instance, as Word documents or a pdf file to the R&D Department. Signed hard copies of completed SUSAR forms should also be sent to the R&D department as soon as possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "5.3.11 Reporting Timeframes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "The table below specifies the reporting timeframes during which the CI should respond to any SAEs, SARs and SUSARs."
            }
        },
        {
            "type": "table",
            "sequence_num": 83,
            "data": {
                "num_rows": 4,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": "Event"
                    },
                    {
                        "text": "Reported by"
                    },
                    {
                        "text": "Report to"
                    },
                    {
                        "text": "Time"
                    },
                    {
                        "text": "All SAEs/SARs (not identifiedin the protocol as expected) and SUSARs Follow-up reports"
                    },
                    {
                        "text": "Researchers / DI"
                    },
                    {
                        "text": "Chief Investigator"
                    },
                    {
                        "text": "within 24 hours ASAP"
                    },
                    {
                        "text": "All fatal/life-threatening SUSARs Follow-up reports"
                    },
                    {
                        "text": "CI or DI"
                    },
                    {
                        "text": "MHRA, HRA & R&D Office"
                    },
                    {
                        "text": "within 7 days Further 8 days"
                    },
                    {
                        "text": "All other SUSARs Follow-up reports"
                    },
                    {
                        "text": "CI or DI"
                    },
                    {
                        "text": "MHRA, HRA & R&D Office"
                    },
                    {
                        "text": "within 15 days As soon as information is available"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 84,
            "data": {
                "num_rows": 1,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": "All SAEs, SARs and SUSARs per IMP for Trust sponsored trials (both expected and unexpected), with a summary of any issues affecting safety of participants."
                    },
                    {
                        "text": "CI or DI"
                    },
                    {
                        "text": "MHRA, HRA & R&D Office"
                    },
                    {
                        "text": "Development Safety Update Report (gSOP- 16)"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "5.4.1 Pregnancy in itself is not regarded as an adverse event unless there is suspicion that  the  study  medication  may  have  interfered  with  the  effectiveness  of  the contraceptive or that it might be harmful to the fetus."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "5.4.2 Should a pregnancy occur, it should be recorded and reported in accordance with the procedures described in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "5.4.3 A pregnancy report form should be completed with the CI/PI's signature (attached as Appendix 5)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "5.4.4 The mother should be followed-up during the course of the pregnancy and the baby should be followed-up for a minimum of three months after birth."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "5.4.5 The mother should give consent for additional follow-up during the course of the pregnancy and once the baby is born."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "5.4.6 Similarly, if the partner of a patient on a clinical trial becomes pregnant, the baby should be monitored for at least three months after birth. Consent needs to be obtained for this additional follow-up."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 1,
                "text": "5.4.7 Any  event  meeting  the  serious  criteria  (death,  life-threatening,  congenital abnormality, birth-defects) should be reported as an SAE. This should be reported accordingly (see section 5.2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Sponsor's Review of Safety Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "5.5.1. The CI should review all SAEs, SARs and SUSARs on an ongoing basis; however independent review by the R&D Department and members of the R&D Steering Group (RDSG) will also take place. Annual reports will be submitted and reviewed by the R&D office."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 A  log  of  all  safety  events  (SAEs/SARs/SUSARs)  should  be  maintained  in  a chronological order from study commencement. The R&D Department will monitor safety trends on an ongoing basis based on study risk. Compliance with safety recording and reporting timeframes will also be routinely assessed as part of the trial monitoring plan however separate pharmacovigilance audits may be performed where necessary."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "5.5.3 A DSUR is required to be submitted annually to the MHRA and REC as per gSOP-"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "prefix": 16.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "5.5.4 It is the responsibility of the CI to ensure a DSUR is submitted per drug on the anniversary of the Development International Birth Date (DIBD). (Please refer to gSOP-16 for detailed guidance)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "5.5.5 A DSUR template is available for download from the hospital intranet and will be prepared in conjunction with the R&D Office."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Urgent Safety Measures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "5.6.1 Urgent Safety Measures are actions which need to be taken to protect participants from any immediate hazard relating to the conduct of the trial or new developments with the IMP, which may affect the safety of the participants."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "5.6.2 Urgent Safety Measures may be taken without prior notification to the MHRA. However, the CI/DI must inform the MHRA, the REC and the R&D Office of the new events, the measures taken and the plan for further action as soon possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "The form for notifying the R&D Office is attached as Appendix"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "Safety Reporting Requirements for nIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "5.7.1 nIMPs are products that are used in accordance with the trial protocol, but which fall outside the IMP definition (e.g. medicines used to assess clinical trial end points such as a radiopharmaceutical used to measure organ function after administration of an IMP, concomitant medication given as part of standard of care for a condition that's not the indication for which the IMP is being tested)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "5.7.2 SUSARs related to nIMPs, where there is a possibility of an intereaction between a nIMP and IMP, must be reported as SUSARs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "5.7.3 If a SUSAR occurs which may be linked to either a nIMP or an IMP, but cannot be attributed to only one of these, the SUSAR must be reported."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "5.7.4 If an adverse reaction associated with the nIMP is likely to affect the safety of the trial subjects, the Sponsor must report this to the MHRA/ REC as an urgent safety measure, a substantial amendment or via a notification to terminate the trial, as applicable."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-01- SOP on SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-04- SAEs (Hosted)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-05- TMF (Sponsored)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-06- Research Staff Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-08- Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-09- Serious Breaches (Sponsored)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-15- DSURs (Sponsored)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "\u25cf EC Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (CT-3) (2011/C 172/01)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Detailed guidance on the request to the competent authorities of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end-of-trial (CT-1) (2010/C 82/01)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to appendix 6)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) - Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "Adverse Reaction (AR) - All untoward and unintended responses to an Investigational medicinal product related to any dose administered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of Investigational Medicinal Product (CTIMP)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Any substance or combination of substances presented for treating or preventing disease in human beings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An IMP is \u2018a pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical trial, including products already with a marketing authorisation but used or assembled (formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or when used to gain further information about the authorised form'"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 1,
                "text": "Pharmacovigilance - The regulations outline procedures for the recording and reporting of safety events (adverse events or suspected unexpected serious adverse reactions) arising from clinical trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) - Any untoward medical occurrence or effect that at any dose that results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "\u25cf death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is life-threatening*"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "text": "\u25cf requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "text": "\u25cf results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "\u25cf is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "text": "* \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 1,
                "text": "Sponsor's Representative - The Director / Assistant Director of R&D will appoint an appropriate staff member to act as the Sponsor's Representative."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 1,
                "text": "Suspected Unexpected Serious Adverse Reaction (SUSAR) - All suspected adverse reactions related to an investigational medicinal product (IMP) that is both unexpected and serious."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 1,
                "text": "Unexpected Adverse Reaction - An adverse reaction, the nature, or severity of which is not consistent with the applicable product information (e.g. investigator's brochure (IB) for an unapproved investigational product or summary of product characteristics (SmPC) for an authorised product)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 1,
                "text": "Unexpected SAE/SAR - An adverse event that meets the definition of serious and is not listed in the protocol, IB, SmPC or the most recent informed consent document for the study (list of unexpected SAE will be trial specific)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: SAE reporting flowchart"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "text": "Please carry out the following assessments for all adverse events."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 1,
                "text": "Seriousness assessment (to be done by a"
            }
        },
        {
            "type": "image",
            "sequence_num": 149,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 1,
                "text": "delegated clinician)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "Was the event listed as a notable event or was the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 1,
                "text": "event serious, resulting in: Adverse Event or Adverse Reaction"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "Death NO Record in the source documents i.e. Life-threatening medical records, CRF, as stated in the Required in-patient hospitalisation or  protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "prolongation of hospitalisation?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "Persistent or significant disability or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "incapacity?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "A congenital abnormality or a birth defect?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "text": "Important medical condition?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 1,
                "text": "YES Exempt SAE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "YES 1. Record on the AE log or as stated in the Was the SAE described in the protocol as being  protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "exempt from expedited reporting?  2. Record on the SAE on research"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "database"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "NO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 1,
                "text": "Causalit  y assessment (to be done by a delegated  NO Serious Adverse Event (SAE)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 1,
                "text": "clinician)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 1,
                "text": "Wa s the SAE suspected to be caused by the  1. Record as per protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "protoc  ol medication?   Notify C.I. or D.I. within  hours of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "text": "knowledge. 3. Record on the SAE on research database"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 0,
                "text": "YES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 1,
                "text": "Expectedness assessment (to be done by a delegated clinician)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 1,
                "text": "Wa s the SAR expected, i.e. was it described in the protocol, Investigator's Brochure or the Summary of P roduct Characteristics as being one of the recognised side effects of the drug?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "NO YES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "text": "Research & Development SAE's Sponsored/ MEHTSOP004/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "text": "Suspected Unexpected Serious Adverse Reaction (SUSAR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Reaction (SAR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: SUSAR Report Form Version 6.0 2017"
            }
        },
        {
            "type": "table",
            "sequence_num": 178,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Date received by R&D Office"
                    },
                    {
                        "text": "ID"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 1,
                "text": "Local Lead"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "text": "Researcher:   Department : Your reference: RD No. __ __ __ __  Short title of study:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 1,
                "text": "Details of SUSAR - please provide details or circle all that apply."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 1,
                "text": "1) Patient's Trial ID Number __ __ __ __"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 1,
                "text": "2) Is this a Trust patient? Yes No"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 1,
                "text": "3a) Patient's age ___ ___ b) Gender Male Female"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 1,
                "text": "4) Medical History ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ____________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ _________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 1,
                "text": "5) Concomitant Medication: ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ____________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ____________________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 1,
                "text": "6) Details of SAE: ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ____________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ______________________________________________________________________________________________________________ ____________________________________________"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 1,
                "text": "7) Type of AE Report: Initial report Follow up report"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 1,
                "text": "8) Date of onset: __ __/__ __/__ __Time of onset: _ _ : _ _ Date event resolved: __ __/__ __/__ __ Still ongoing - - - - - - - - - -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 1,
                "text": "9) Trial drug : Date of last dose: _ _ / _ _ / _ _ _ _ Time of last dose: _ _ : _ _  10a) Event terms and CTCAE grading:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 1,
                "text": "10b) Which version of the CTCAE was used? Version 3.0 Version 4.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 1,
                "text": "11) Seriousness assessment (please circle)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "Death Life-threatening Hospitalisation or Prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "Disability Congenital abnormality Important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 1,
                "text": "12) Causality assessment by CI/ PI- is there a possible causal relationship between this adverse event and the trial drug?"
            }
        },
        {
            "type": "table",
            "sequence_num": 196,
            "data": {
                "num_rows": 3,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": "Causality"
                    },
                    {
                        "text": "Definitely"
                    },
                    {
                        "text": "Probably"
                    },
                    {
                        "text": "Possibly"
                    },
                    {
                        "text": "Unlikely"
                    },
                    {
                        "text": "Unrelated"
                    },
                    {
                        "text": "Trial Drug"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 1,
                "text": "13) Severity of event:  Mild Moderate Severe"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 1,
                "text": "14) Outcome: Recovered Recovering Recovered with sequelae Not recovered Unknown Fatal"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 1,
                "text": "15) Expectedness assessment by CI/ PI \u2013 is this event expected as described in the protocol, Investigator's Brochure (IB) or Summary of Product Characteristics (SPC)?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 1,
                "text": "Expectedness"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 1,
                "text": "Expected*  Unexpected Trial Drug"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 1,
                "text": "*(Expected events do not need to be reported to the R&D Office)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 1,
                "text": "16) Please indicate which document(s) were used to check expectedness: Protocol IB SPC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 1,
                "text": "For all SUSARs and SAEs please notify the sponsor as per their requirement. Where the Trust is the sponsor, please notify the MHRA and Research Ethics Committee of all SUSARs, in line with the Trust SOP gSOP-02."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 1,
                "text": "Local Lead Researcher Comments: (View on SUSAR and the implications for ongoing trial.)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 1,
                "text": "Sponsor Assessment of Causality and Expectedness"
            }
        },
        {
            "type": "image",
            "sequence_num": 207,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 0,
                "text": "Sponsor approval of Causality Assessment (Please circle): Yes No"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 0,
                "text": "If \u2018No' please provide details:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "text": "Sponsor approval of Expectedness Assessment (Please circle): Yes No If \u2018No' please provide details:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 0,
                "text": "Recommended Actions (where required):"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 1,
                "text": "Sponsor Representative Signature\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date____/____/____"
            }
        },
        {
            "type": "image",
            "sequence_num": 213,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.006.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 1,
                "text": "For Trust sponsored trials, please provide dates that this event was reported to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 1,
                "text": "MHRA __ __/__ __/__ __ Main REC __ __/__ __/__ __ Other participating sites (for multi-centre studies) __ __/__ __/__ _ For Trust hosted studies please give the date this event was reported to the sponsor __ __/__ __/__ __"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 1,
                "text": "CI/PI/DI signature\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date____/____/____"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 1,
                "text": "Print Name \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 1,
                "text": "Return completed form, with accompanying Serious Adverse Event Report Form to: the R&D Department"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 1,
                "text": "Appendix 4: Notification of Amendment for Urgent Safety Measures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 1,
                "text": "Please complete this form to the R&D Office as soon as possible after implementation of Urgent Safety Measure. This form should only be in exceptional circumstances, for example to protect the participants from an immediate hazard to their welfare or safety"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 1,
                "text": "Part A \u2013 Where to Send your Request"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 1,
                "text": "To:  R&D Office  R&D Office use only"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "text": "Date received:"
            }
        },
        {
            "type": "image",
            "sequence_num": 224,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 1,
                "text": "Part B \u2013 Your Details From:"
            }
        },
        {
            "type": "image",
            "sequence_num": 226,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.008.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 0,
                "text": "Tel:   Fax:   Email:"
            }
        },
        {
            "type": "image",
            "sequence_num": 228,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.012.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 1,
                "text": "Part C \u2013 Sponsor Details"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 0,
                "text": "(please tick) Trust-sponsored"
            }
        },
        {
            "type": "image",
            "sequence_num": 231,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.013.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 232,
            "data": {
                "is_heading": 0,
                "text": "Trust-hosted (please specify below)"
            }
        },
        {
            "type": "image",
            "sequence_num": 233,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.016.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 1,
                "text": "Part D \u2013 Study Details Trial Name:"
            }
        },
        {
            "type": "image",
            "sequence_num": 235,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.018.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 236,
            "data": {
                "is_heading": 1,
                "text": "CTIMP OR non-CTIMP (please delete as appropriate)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 237,
            "data": {
                "is_heading": 0,
                "text": "RD reference number:  RD"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 0,
                "text": "Chief Investigator:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 239,
            "data": {
                "is_heading": 0,
                "text": "Principal Investigator:"
            }
        },
        {
            "type": "image",
            "sequence_num": 240,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.020.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 1,
                "text": "Part E \u2013 Urgent Measures"
            }
        },
        {
            "type": "table",
            "sequence_num": 242,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Measures taken:"
                    },
                    {
                        "text": "Date effective from:"
                    },
                    {
                        "text": "Why have these measures been taken:"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 243,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator Signature"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 244,
            "data": {
                "is_heading": 1,
                "text": "Date"
            }
        },
        {
            "type": "image",
            "sequence_num": 245,
            "data": {
                "url": "MEHTSOP004 Research & Development SAE\u2019s Sponsored 1.0.022.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 246,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Appendix 5: Pregnancy Notification Form version 2.0 th January 2013"
            }
        },
        {
            "type": "table",
            "sequence_num": 247,
            "data": {
                "num_rows": 6,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "RD number _ _ _ _ Your reference"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Short title of study"
                    },
                    {
                        "text": "Chief Investigator Department"
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___ ___"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 248,
            "data": {
                "num_rows": 17,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "MATERNAL INFORMATION"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Date of Birth _ _/_ _/_ _ _ _ Date of last menstrual period _ _/_ _/_ _ _ _ Expected Date of Delivery _ _/_ _/_ _ _ _ Method of contraception: Was contraception used as instructed? Yes No Uncertain"
                    },
                    {
                        "text": "MEDICAL HISTORY"
                    },
                    {
                        "text": "Include information in familial disorders, known risk factors or conditions that may affect the outcome of the pregnancy. (If none, mark as N/A)"
                    },
                    {
                        "text": "PREVIOUS OBSTETRIC HISTORY"
                    },
                    {
                        "text": "(provide details on all previous pregnancies, including termination or stillbirth) Gestation Week Outcome including any abnormalities 1 2 3"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "DRUG INFORMATION"
                    },
                    {
                        "text": "Drug name"
                    },
                    {
                        "text": "Dose"
                    },
                    {
                        "text": "Route"
                    },
                    {
                        "text": "Date start"
                    },
                    {
                        "text": "Date stopped"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 249,
            "data": {
                "num_rows": 14,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "PRENATAL INFORMATION"
                    },
                    {
                        "text": "Have any specific tests, e.g. amniocentesis, ultrasound, maternal serum AFP, been performed during the pregnancy so far? Yes No Not known If Yes, please specify test date and results: Test type and date _ _/_ _/_ _ _ _ Result"
                    },
                    {
                        "text": "PREGNANCY OUTCOME"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___ ___"
                    },
                    {
                        "text": "MATERNAL PREGNANCY ASSOCIATED EVENTS"
                    },
                    {
                        "text": "If the mother experiences an SAE during the pregnancy, please indicate here and complete an SAE form, complete with CI's signature."
                    },
                    {
                        "text": "CHILD OUTCOME"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 250,
            "data": {
                "num_rows": 11,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "(a) Pregnancy Loss Yes No If Yes Therapeutic Planned Spontaneous Please specify the reason and any abnormalities (if known): Date _ _/_ _/_ _ _ _"
                    },
                    {
                        "text": "(b) Delivery Yes No If Yes Normal Forceps/Ventouse Caesarean Date of delivery _ _/_ _/_ _ _ _ Delivery at week: Delivery was: Normal Abnormal Stillborn Please give dates and details of any abnormalities"
                    },
                    {
                        "text": "Sex Male Female Height cm Weight kg Head circumference cm AGPAR score 1minute _ _ 5 minutes _ _ 10 minutes _ _"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Patient's Trial ID Number __ __ __ __ Date of birth ___ ___ / ___ ___ /___ ___"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "ASSESSMENT OF SERIOUSNESS (OF PREGNANCY OUTCOME)"
                    },
                    {
                        "text": "Not serious Serious : a) Mother died/baby died b) Life-threatening c) Involved prolonged inpatient hospitalisation d) Results in persistent or significant disability/incapacity e) Congenital anomaly/birth defect f) Other significant medical events Date of death: _ _/_ _/_ _ _ _"
                    },
                    {
                        "text": "ASSESSMENT OF CAUSALITY(OF PREGNANCY OUTCOME)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 251,
            "data": {
                "num_rows": 12,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Please indicate the relationship between the trial drugs and the pregnancy outcome"
                    },
                    {
                        "text": "Causality"
                    },
                    {
                        "text": "Definitely"
                    },
                    {
                        "text": "Probably"
                    },
                    {
                        "text": "Possibly"
                    },
                    {
                        "text": "Unlikely"
                    },
                    {
                        "text": "Unrelated"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Trial Drug(s)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Could the trial drugs have interfered with contraception? a) Yes b) No c) Maybe"
                    },
                    {
                        "text": "ANY ADDITIONAL INFORMATION"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "DETAILS OF PERSON SUBMITTING THIS REPORT"
                    },
                    {
                        "text": "Signature \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date _ _/_ _/_ _ _ _ Please print name \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. CI/PI signature\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Date _ _/_ _/_ _ _ _"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 252,
            "data": {
                "is_heading": 0,
                "text": "Research & Development SAE's Sponsored/ MEHTSOP004/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 253,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 254,
            "data": {
                "is_heading": 0,
                "text": "Research & Development SAE's Sponsored/ MEHTSOP004/ 1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 255,
            "data": {
                "is_heading": 1,
                "text": "Appendix 6: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 256,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development SAE's Sponsored/ MEHTSOP004/ 1.0"
            }
        },
        {
            "type": "table",
            "sequence_num": 257,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 258,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 259,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Laura Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 260,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": ""
            }
        }
    ]
}